MetLife Investment Management, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 184 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.

Quarter-by-quarter ownership
MetLife Investment Management, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$400,464
+184.1%
21,600
+69.5%
0.00%
+200.0%
Q2 2023$140,982
-17.6%
12,7470.0%0.00%0.0%
Q1 2023$171,192
+8.6%
12,7470.0%0.00%0.0%
Q4 2022$157,680
-11.3%
12,7470.0%0.00%
-50.0%
Q3 2022$177,821
-21.8%
12,747
-22.6%
0.00%0.0%
Q2 2022$227,534
-15.1%
16,4760.0%0.00%0.0%
Q1 2022$268,065
+46.7%
16,476
+46.9%
0.00%0.0%
Q4 2021$182,692
+9.7%
11,2150.0%0.00%0.0%
Q3 2021$166,543
-25.6%
11,2150.0%0.00%0.0%
Q2 2021$223,964
-13.5%
11,2150.0%0.00%0.0%
Q1 2021$258,842
-6.6%
11,2150.0%0.00%
-33.3%
Q4 2020$277,011
-40.4%
11,2150.0%0.00%
-40.0%
Q3 2020$464,974
-13.5%
11,2150.0%0.01%
-16.7%
Q2 2020$537,311
-23.9%
11,2150.0%0.01%
-40.0%
Q1 2020$706,096
-49.2%
11,2150.0%0.01%
-28.6%
Q4 2019$1,389,763
+86.7%
11,2150.0%0.01%
+75.0%
Q3 2019$744,227
-16.6%
11,2150.0%0.01%
-20.0%
Q2 2019$892,375
-17.6%
11,215
+15.9%
0.01%
-16.7%
Q1 2019$1,082,581
+11.0%
9,6780.0%0.01%0.0%
Q4 2018$975,446
-16.3%
9,678
+4.9%
0.01%0.0%
Q3 2018$1,165,671
+36.8%
9,225
-9.1%
0.01%
+20.0%
Q2 2018$852,00010,1530.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2020
NameSharesValueWeighting ↓
WHITE SQUARE CAPITAL LLP 65,500$7,117,00011.05%
Ghost Tree Capital, LLC 70,000$7,606,0001.83%
Carmignac Gestion 2,022,792$219,776,0001.71%
Orbimed Advisors 1,120,000$121,688,0001.55%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 29,555$3,211,0001.45%
Parametrica Management Ltd 10,814$1,175,0001.16%
BB BIOTECH AG 255,719$27,784,0001.03%
SECTORAL ASSET MANAGEMENT INC 74,150$8,056,0000.89%
ALTRINSIC GLOBAL ADVISORS LLC 188,904$20,524,0000.76%
FALCON POINT CAPITAL, LLC 45,005$4,890,0000.66%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders